Lonhala Magnair

Medical Editor: John P. Cunha, DO, FACOEP Last updated on RxList: 3/10/2022
Lonhala Magnair Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What Is Lonhala Magnair?

Lonhala Magnair (glycopyrrolate) Inhalation Solution is an anticholinergic indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

What Are Side Effects of Lonhala Magnair?

Common side effects of Lonhala Magnair include:

Dosage for Lonhala Magnair/h4>

The dose of Lonhala Magnair for maintenance treatment of COPD is the contents of one Lonhala vial twice-daily.

What Drugs, Substances, or Supplements Interact with Lonhala Magnair?

Lonhala Magnair may interact with other anticholinergic drugs. Tell your doctor all medications and supplements you use.

Lonhala Magnair During Pregnancy or Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant before using Lonhala Magnair; it is unknown how it would affect a fetus. It is unknown if Lonhala Magnair passes into breast milk. Consult your doctor before breastfeeding.

Additional Information

Our Lonhala Magnair (glycopyrrolate) Inhalation Solution, for Oral Inhalation Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


COPD (chronic obstructive pulmonary disease) is the same as adult-onset asthma. See Answer
Lonhala Magnair Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • wheezing, choking, or other breathing problems after using this medicine;
  • blurred vision, tunnel vision, eye pain or redness, seeing halos around lights;
  • nausea, vomiting; or
  • painful or difficult urination, little or no urination.

Common side effects may include:

  • cold symptoms such as stuffy nose, sneezing, sore throat;
  • feeling short of breath; or
  • burning when you urinate.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Lonhala Magnair (Glycopyrrolate Inhalation Solution)


COPD Foods to Boost Your Health - COPD Diet Tips See Slideshow
Lonhala Magnair Professional Information


The following adverse reactions are described in greater detail in other sections:

  • Paradoxical bronchospasm [see WARNINGS AND PRECAUTIONS]
  • Immediate hypersensitivity reactions [see WARNINGS AND PRECAUTIONS]
  • Worsening of narrow-angle glaucoma [see WARNINGS AND PRECAUTIONS]
  • Worsening of urinary retention [see WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The LONHALA MAGNAIR safety database included 2379 subjects with COPD in two 12-week efficacy studies and one 48-week long-term safety study. A total of 431 subjects received treatment with LONHALA MAGNAIR 25 mcg twice-daily (BID). The safety data described below are based on the two 12-week trials and the one 48-week trial.

12-Week Trials

LONHALA MAGNAIR was studied in two 12-week placebo-controlled trials in subjects with COPD. In these trials, 431 subjects were treated with LONHALA MAGNAIR at the recommended dose of 25 mcg twice daily. The population had a mean age of 63 years (ranging from 40 to 87 years), with 56% males, 90% Caucasian, and a mean post-bronchodilator forced expiratory volume in one second (FEV1) percent predicted of 52% of predicted normal value (20%-80%) at study entry. The study population also included subjects with pre-existing cardiovascular disease as well as subjects with continued use of stable long-acting bronchodilator (LABA) ± inhaled corticosteroid (ICS) and ipratropium bromide background therapy. Subjects with unstable cardiac disease, narrow-angle glaucoma, or symptomatic prostatic hypertrophy or bladder outlet obstruction were excluded from these studies.

Table 1 shows the most common adverse reactions incidence greater than or equal to 2.0% in the LONHALA MAGNAIR group and higher than placebo in the two 12-week placebo-controlled trials.

The proportion of subjects who discontinued treatment due to adverse reactions was 5% for the LONHALA MAGNAIR-treated subjects and 9% for placebo-treated subjects.

Table 1. Adverse Reactions with LONHALA MAGNAIR ≥2.0% Incidence and Higher than Placebo

N (%)
MAGNAIR 25 mcg
N (%)
Dyspnea 13 (3.0) 21 (4.9)
Urinary Tract Infection 6 (1.4) 9 (2.1)

Other adverse reactions defined as events with an incidence of ≥1.0% but less than 2.0% with LONHALA MAGNAIR but more common than with placebo included the following: wheezing, upper respiratory tract infection, nasopharyngitis, oedema peripheral, and fatigue.

48-Week Trial

In a long-term open-label safety trial, 1086 subjects were treated for up to 48-weeks with LONHALA MAGNAIR 50 mcg twice-daily (N=620) or tiotropium (N=466). The demographic and baseline characteristics of the long-term safety trial were similar to those of the placebo-controlled efficacy studies described above. The adverse reactions reported in the long-term safety trial were consistent with those observed in the placebo-controlled studies of 12-weeks. Adverse reactions that occurred at a frequency greater than that seen in either active treatment dose in the pooled 12-week placebo controlled studies and ≥ 2.0% were: diarrhea, edema peripheral, bronchitis, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, urinary tract infection, back pain, headache, Chronic Obstructive Pulmonary Disease, cough, dyspnea, oropharyngeal pain, and hypertension.

Read the entire FDA prescribing information for Lonhala Magnair (Glycopyrrolate Inhalation Solution)

© Lonhala Magnair Patient Information is supplied by Cerner Multum, Inc. and Lonhala Magnair Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors